Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines

Gene Therapy

Volumn 8, Issue 20, 2001, Pages 1515-1523

  Withoff, S ^a   Glazenburg, K L ^a   Van Veen, M L ^a   Kraak, M M J ^a   Hospers, G A P ^a   Storkel S ^b   De Vries, E G E ^a   Wilschut, J ^a   Daemen, T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Autologus tumor cell vaccine; Cytokine gene transfer; Gene therapy; GM CSF; Semliki Forest virus

Indexed keywords

BETA GALACTOSIDASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR CELL VACCINE; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; BACTERIUM TRANSDUCTION; BONE MARROW CELL; CANCER CELL CULTURE; CARCINOMA CELL; CELL GROWTH; CYTOKINE PRODUCTION; DEFECTIVE VIRUS; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPORTER GENE; RETROVIRUS; SEMLIKI FOREST ALPHAVIRUS; TUMOR CELL; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ARTIFICIAL GENE FUSION; BETA-GALACTOSIDASE; CANCER VACCINES; CARCINOMA, RENAL CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ACTIVE; KIDNEY NEOPLASMS; MICE; SEMLIKI FOREST VIRUS; TRANSDUCTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; TUMOR CELLS, CULTURED; VIROSOMES;

EID: 0035163322     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301556     Document Type: Article

References (52)

1. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte - Macrophage colony-stimulating factor gene transfer
2. A phase I clinical trial of immunotherapy with interferon-gamma gene modified autologous melanoma cells: Monitoring the humoral immune response
3. Cytokine gene therapy of cancer using interleukin-12: Murine and clinical trials
4. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte - Macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
5. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte - Macrophage colony-stimulating factor
6. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
7. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte - Macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity
8. High efficiency gene transfer into primary human tumor explants without cell selection
9. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8(+) cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system
10. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells
11. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte - Macrophage colony-stimulating factor gene transfer
12. Antitumor effect induced by granulocyte/macrophage colony-stimulating factor gene-modified tumor vaccination: Comparison of adenovirus- and retrovirus-mediated genetic transduction
13. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained antitumor immunity prolongs animal survival
14. Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine
15. Semliki Forest virus expression system: Production of conditionally infectious recombinant particles
16. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon
17. A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene
18. Two-helper RNA system for production of recombinant Semliki Forest virus particles
19. The alphaviruses: Gene expression, replication, and evolution
20. Regulators on the road to persistent alphavirus infection
21. The molecular pathogenesis of Semliki Forest virus: A model virus made useful?
22. Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papiloma-virus type 16 E6 and E7
23. Generation of cytotoxic and humoral immune responses by non-replicative recombinant Semliki Forest virus
24. Recombinant Semliki Forest virus particles expressing louping ill virus antigen induce better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine
25. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene
26. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
27. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type I envelope protein and challenge with a high dose of SHIV-4 virus
28. Effect of intraperitoneally administered recombinant murine granulocyte - Macrophage colony-stimulating factor (rmGM-CSF) on the cytotoxic potential of murine peritoneal cells
29. Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF
30. Retrovirus mediated transfer and expression of GM-CSF in haematopoietic cells
31. Strategies for cancer gene therapy
32. Interpreting cancer vaccine clinical trials
33. Immunotherapy of cancer
34. Gene-based cancer vaccines: An ex vivo approach
35. The use of dendritic cells for cancer vaccination
36. Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal
37. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma
38. Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: Expression of IL-12 in human tumor cells
39. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography
40. Enhancing immune responses using suicidal DNA vaccines
41. Death mechanisms in cultured cells infected by Semliki Forest virus
42. Cancer therapy using a self-replicating RNA vaccine
43. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors
44. The promise of nucleic acid vaccines
45. Semliki Forest virus-based vaccines: Persistence, distribution and pathological analysis in two animal systems
46. Cancer vaccines: The interleukin 2 dosage effect
47. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model
48. Modified Semliki Forest virus expression vector that facilitates cloning
49. Initial DNA damage or repair as the major determinant of cellular radiosensitivity?
50. Single proline substitutions in predicted α-helices of murine granulocyte - Macrophage colony-stimulating factor result in a loss in bioactivity and altered glycosylation
51. The amino-terminal helix of GM-CSF and IL-5 governs high affinity binding to their receptors
52. The identification and characterization of a novel human differentiation-inhibiting protein that selectively blocks erythroid differentiation